#MochidaPharmaceutical

For the third quarter of the fiscal year ending March 2026, net sales were ¥87,487 million (up 8.4% YoY), operating income was ¥7,526 million (up 3.9% YoY), and net income attributable to owners of parent was ¥6,342 million (up 13.2% YoY), demonstrating steady business performance.

For the fiscal year ending March 2026, net sales have been upwardly revised to JPY 115.5 billion (4.5% increase from previous forecast), operating income to JPY 9.5 billion (35.7% increase), and net income attributable to owners of parent to JPY 8.4 billion (55.6% increase).